Talis Biomedical Management

Management criteria checks 1/4

Talis Biomedical's CEO is Rob Kelley, appointed in Dec 2021, has a tenure of 2.42 years. total yearly compensation is $1.02M, comprised of 54.1% salary and 45.9% bonuses, including company stock and options. directly owns 0.037% of the company’s shares, worth $5.89K. The average tenure of the management team and the board of directors is 1.8 years and 2.4 years respectively.

Key information

Rob Kelley

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage	54.1%
CEO tenure	2.4yrs
CEO ownership	0.04%
Management average tenure	1.8yrs
Board average tenure	2.4yrs

Recent management updates

Recent updates

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Nov 04

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Jul 21

News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

May 18

Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 14

CEO Compensation Analysis

How has Rob Kelley's remuneration changed compared to Talis Biomedical's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$1m	US$551k	-US$62m
Sep 30 2023	n/a	n/a	-US$75m
Jun 30 2023	n/a	n/a	-US$86m
Mar 31 2023	n/a	n/a	-US$98m
Dec 31 2022	US$2m	US$525k	-US$113m
Sep 30 2022	n/a	n/a	-US$115m
Jun 30 2022	n/a	n/a	-US$127m
Mar 31 2022	n/a	n/a	-US$165m
Dec 31 2021	US$2m	US$322k	-US$192m
Sep 30 2021	n/a	n/a	-US$208m
Jun 30 2021	n/a	n/a	-US$199m
Mar 31 2021	n/a	n/a	-US$144m
Dec 31 2020	US$2m	US$89k	-US$91m

Compensation vs Market: Rob's total compensation ($USD1.02M) is above average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.

CEO

Rob Kelley (51 yo)

2.4yrs

Tenure

US$1,019,331

Compensation

Mr. Robert Kelley, also known as Rob, MBA, has been Chief Executive Officer and Director of Talis Biomedical Corporation since December 8, 2021 and served as its Chief Commercial Officer since September 20...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Robert Kelley	CEO & Director	2.4yrs	US$1.02m	0.037% $ 5.9k
Andrew Lukowiak	President & Chief Scientific Officer	less than a year	US$1.05m	no data
Rustem Ismagilov	Co-Founder & Director	no data	US$89.22k	0.97% $ 152.7k
Rebecca Markovich	Interim Chief Financial Officer	1.1yrs	US$468.23k	0% $ 0
Liang Li	Co-Founder and Director of Technology & Strategy	no data	no data	no data
Emily Faucette	Senior Vice President of Corporate Communications & Investor Relations	3.3yrs	no data	no data
Jill Green	Senior Vice President of Legal	no data	no data	no data
Matthew Pepe	Vice President of Human Resource	no data	no data	no data
Margaret Barrett	Controller	no data	no data	no data
Gillian Green	Company Secretary	no data	no data	no data

1.8yrs

Average Tenure

49.5yo

Average Age

Experienced Management: TLIS's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Robert Kelley	CEO & Director	2.4yrs	US$1.02m	0.037% $ 5.9k
Rustem Ismagilov	Co-Founder & Director	10.9yrs	US$89.22k	0.97% $ 152.7k
Kimberly Popovits	Lead Independent Director	2.4yrs	US$117.10k	0.76% $ 119.4k
Randal Scott	Independent Director	8.3yrs	US$100.27k	6.31% $ 990.3k
Matthew Posard	Independent Director	8.2yrs	US$99.27k	0.23% $ 35.9k
Heinrich Dreismann	Independent Director	less than a year	US$34.18k	0.015% $ 2.4k
Raymond Cheong	Director	1.2yrs	US$45.29k	0% $ 0

2.4yrs

Average Tenure

56yo

Average Age

Experienced Board: TLIS's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Talis Biomedical Management

Management criteria checks 1/4

Key information

Recent management updates

Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors

Talis Biomedical Corporation Appoints Kimberly Popovits as Lead Independent Director

Less than half of directors are independent

Talis Biomedical Corporation Announces Resignation of Raymond Cheong from Board of Directors

Less than half of directors are independent

Talis Biomedical Corporation Announces Board Changes

Recent updates

Talis Biomedical Corporation to Report Q2, 2023 Results on Aug 10, 2023

Talis Biomedical Corporation Announces New Data Supporting the Development of Its Planned CT/NG/TV and Vinal Infections Panels

Talis Biomedical Announces 1-For-15 Reverse Stock Split to Regain Compliance

Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors

Talis Biomedical Corporation Appoints Kimberly Popovits as Lead Independent Director

Talis Biomedical Corporation to Report Q1, 2023 Results on May 11, 2023

Talis Biomedical Transfers the Listing of Its Securities to the Nasdaq Capital Market

Price target decreased to US$0.40

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.98 loss per share (vs US$1.49 loss in 3Q 2021)

We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Talis Biomedical reports Q2 results

Talis Biomedical Corporation Announces Resignation of Raymond Cheong from Board of Directors

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$1.25

Less than half of directors are independent

Talis Biomedical Corporation Announces Board Changes

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Talis Biomedical Aims For Manufacturing Turnaround

Talis Biomedical Corporation to Report Q4, 2021 Results on Mar 15, 2022

The Klein Law Firm Announces Lead Plaintiff Deadline of March 8, 2022 in the Class Action Filed on Behalf of Talis Biomedical Corporation Shareholders

Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Talis Biomedical Corporation

Levi & Korsinsky, LLP Notifies Shareholders of Talis Biomedical Corporation of A Class Action Lawsuit and A Lead Plaintiff Deadline

Glancy Prongay & Murray LLP Files Securities Lawsuit Against Talis Biomedical Corporation

Less than half of directors are independent

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$13.90 loss in 3Q 2020)

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates fall to US$11.2m

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Talis Biomedical Corporation(NasdaqGM:TLIS) dropped from Russell Microcap Growth Index

Independent Director recently bought US$203k worth of stock

News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2021 earnings released: US$4.61 loss per share (vs US$56.61 profit in 1Q 2020)

Full year 2020 earnings released: US$42.98 loss per share (vs US$34.34 profit in FY 2019)

Talis Appoints Jeryl Hilleman to Board of Directors

Talis Biomedical Corporation Provides Update on Regulatory Pathway for Emergency Use Authorization (EUA) of Its Talis One™ Covid-19 Test

Talis Biomedical Corporation has completed an IPO in the amount of $220.8 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age